My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Merck & Co (NY:MRK)

122.26 +0.40 (+0.33%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

99 100 Next >

MarketBeat Week in Review – 11/4 - 11/8

November 09, 2024

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

Via MarketBeat

Topics Economy Government

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗

November 08, 2024

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and...

Via Benzinga

2 Hot Biopharma Stocks to Buy and Hold for 5 Years ↗

November 08, 2024

If you're patient, these businesses have a lot of promising projects in the works.

Via The Motley Fool

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows. ↗

November 07, 2024

These stocks have seen better days but investors shouldn't count them out in the long run.

Via The Motley Fool

Why NYSE:MRK is a Top Pick for Dividend Investors. ↗

November 04, 2024

Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock.

Via Chartmill

Is Merck Stock a Buy? ↗

November 01, 2024

The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.

Via The Motley Fool

NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases. ↗

October 30, 2024

MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals.

Via Chartmill

Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

November 07, 2024

Via Benzinga

Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom ↗

November 06, 2024

Broadcom expanded its multi-year partnership with Telia Company to advance telecom and cloud infrastructure using VMware's product portfolio.

Via Benzinga

2 Magnificent Stocks to Buy That Are Near 52-Week Lows ↗

November 05, 2024

These stocks near 52-week lows could be ready to rebound.

Via The Motley Fool

Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings

November 05, 2024

After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors.

Via MarketBeat

Topics Intellectual Property

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo ↗

November 04, 2024

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.

Via Benzinga

A Look Into Merck & Co Inc's Price Over Earnings ↗

October 29, 2024

Via Benzinga

Where Will Merck Be in 5 Years? ↗

October 25, 2024

There's a lot to like here.

Via The Motley Fool

Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?

November 04, 2024

Summit Therapeutics Inc. aims to advance Ivonescimab, a potential breakthrough for NSCLC. The FDA's Fast Track designation boosts its U.S. clinical pathway.

Via MarketBeat

Is Pfizer Stock a Bargain for Long-Term Investors? ↗

November 04, 2024

Wall Street's bearish take on this proven innovator may not be warranted.

Via The Motley Fool

Is It Time to Buy October's Worst-Performing Dow Jones Stocks? ↗

November 03, 2024

The Dow finished October down slightly. Should you buy any of these blue chips?

Via The Motley Fool

Topics Stocks

3 Magnificent Stocks Under $100 to Buy in November ↗

November 03, 2024

The price could be right for these stocks.

Via The Motley Fool

2 Dividend Stocks to Buy for a Lifetime of Passive Income ↗

November 02, 2024

These are the kinds of stocks that can allow investors to sleep easy at night.

Via The Motley Fool

Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease ↗

November 01, 2024

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with Winrevair showing promising performance.

Via Benzinga

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗

November 01, 2024

The major indexes declined, but haven't fallen apart.

Via Investor's Business Daily

Merck (MRK) Q3 2024 Earnings Call Transcript ↗

October 31, 2024

MRK earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday? ↗

October 31, 2024

Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months.

Via Benzinga

Merck Q3 Earnings And Revenues Top Estimates ↗

October 31, 2024

Merck came out with quarterly earnings of $1.57 per share.

Via Talk Markets

Merck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand ↗

October 31, 2024

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.

Via Benzinga

Will Merck's Guidance Cut Prove Gruesome In The Wake Of Januvia, Gardasil Misses? ↗

October 31, 2024

The company also reported light sales of HPV vaccine Gardasil and diabetes meds Januvia/Janumet.

Via Investor's Business Daily

3 Dividend Stocks That Could Raise Their Payouts in November ↗

October 31, 2024

These dividend stocks can be excellent options for buy-and-hold investors.

Via The Motley Fool

Why Is Moderna Stock Trading Higher On Monday? ↗

October 28, 2024

Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies.

Via Benzinga

What Lies In Store For Healthcare ETFs In Q3 Earnings? ↗

October 27, 2024

The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited.

Via Talk Markets

Topics ETFs

Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades' ↗

October 25, 2024

Pfizer shares fell 0.8% to close at $28.64 during Thursday's session. Live Nation Entertainment shares gained 1.5% to close at $116.45.

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.